Therapeutic efficacy of lenvatinib for stage IVC anaplastic thyroid cancer
Thyroid World Congress ePoster Library. Iwasaki H. 06/20/19; 272083; 34
Hiroyuki Iwasaki
Hiroyuki Iwasaki
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

【Background】Anaplastic thyroid carcinoma (ATC) is an orphan disease with a very poor prognosis. The unresectable stage IVC of ATC in particular is extremely difficult to treat; its prognosis is only a few months even when treated with irradiation and/or chemotherapy. In 2015, lenvatinib was approved for clinical use against ATC in Japan. In the present study, we evaluated the efficacy of lenvatinib for stage IVC ATC.

【Methods】Twenty-eight patients with pathologically confirmed stage IVC ATC treated at Kanagawa Cancer Center from 2011 to 2018 were included in this study. Of these, seven patients were treated with weekly Paclitaxel (PTX group), 7 refused treatment (BSC group), and 14 were treated with lenvatinib (LT group). The respective survival curves were analyzed using the logrank test.

【Results】The median overall survival was 4.25 months for the LT group, 2.30 for the PTX group, and 2.00 for the BSC group. A statistically significant survival benefit was observed in the LT group (p = 0.014). There were no patients in the PTX group and five patients in the LT group (35.7%) whose tumor size reduced by 30% or more in the first month after treatment.

【Conclusions】The LT group demonstrated a median survival benefit of about 2 months over both the PTX group and the BSC group. Although tumor shrinkage of 30% or more was confirmed in five patients treated with lenvatinib, two treatment deaths occurred. These results suggest that an appropriate dose reduction is necessary.

 


【Background】Anaplastic thyroid carcinoma (ATC) is an orphan disease with a very poor prognosis. The unresectable stage IVC of ATC in particular is extremely difficult to treat; its prognosis is only a few months even when treated with irradiation and/or chemotherapy. In 2015, lenvatinib was approved for clinical use against ATC in Japan. In the present study, we evaluated the efficacy of lenvatinib for stage IVC ATC.

【Methods】Twenty-eight patients with pathologically confirmed stage IVC ATC treated at Kanagawa Cancer Center from 2011 to 2018 were included in this study. Of these, seven patients were treated with weekly Paclitaxel (PTX group), 7 refused treatment (BSC group), and 14 were treated with lenvatinib (LT group). The respective survival curves were analyzed using the logrank test.

【Results】The median overall survival was 4.25 months for the LT group, 2.30 for the PTX group, and 2.00 for the BSC group. A statistically significant survival benefit was observed in the LT group (p = 0.014). There were no patients in the PTX group and five patients in the LT group (35.7%) whose tumor size reduced by 30% or more in the first month after treatment.

【Conclusions】The LT group demonstrated a median survival benefit of about 2 months over both the PTX group and the BSC group. Although tumor shrinkage of 30% or more was confirmed in five patients treated with lenvatinib, two treatment deaths occurred. These results suggest that an appropriate dose reduction is necessary.

 


    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings